Sivik Global Healthcare LLC increased its stake in shares of Eli Lilly And Co (NYSE:LLY) by 27.3% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,000 shares of the company’s stock after buying an additional 15,000 shares during the quarter. Eli Lilly And Co comprises approximately 3.3% of Sivik Global Healthcare LLC’s investment portfolio, making the stock its 2nd biggest position. Sivik Global Healthcare LLC’s holdings in Eli Lilly And Co were worth $9,083,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. Oregon Public Employees Retirement Fund raised its position in Eli Lilly And Co by 17,720.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 42,420,406 shares of the company’s stock worth $367,000 after purchasing an additional 42,182,367 shares during the last quarter. Norges Bank bought a new position in shares of Eli Lilly And Co in the 4th quarter worth about $1,056,086,000. FMR LLC raised its position in shares of Eli Lilly And Co by 83.9% in the 4th quarter. FMR LLC now owns 13,687,081 shares of the company’s stock worth $1,583,870,000 after acquiring an additional 6,242,865 shares in the last quarter. Amundi Pioneer Asset Management Inc. raised its position in shares of Eli Lilly And Co by 165.4% in the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 6,012,822 shares of the company’s stock worth $695,804,000 after acquiring an additional 3,747,482 shares in the last quarter. Finally, BlackRock Inc. raised its position in shares of Eli Lilly And Co by 3.0% in the 4th quarter. BlackRock Inc. now owns 68,956,519 shares of the company’s stock worth $7,979,649,000 after acquiring an additional 2,030,845 shares in the last quarter. 79.38% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have recently weighed in on the company. Credit Suisse Group set a $121.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Friday, March 22nd. Bank of America set a $129.00 price objective on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Thursday, March 21st. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $142.00 price objective for the company in a research report on Wednesday, April 10th. Guggenheim downgraded Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price for the company. in a research note on Thursday, April 11th. Finally, UBS Group began coverage on Eli Lilly And Co in a research note on Wednesday, March 20th. They issued a “buy” rating and a $74.51 target price for the company. Ten research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $119.99.
Eli Lilly And Co (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, topping analysts’ consensus estimates of $1.32 by $0.01. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The company had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $5.12 billion. During the same quarter in the previous year, the firm posted $1.31 EPS. Eli Lilly And Co’s revenue was up 2.6% on a year-over-year basis. On average, equities analysts expect that Eli Lilly And Co will post 5.66 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be given a $0.645 dividend. The ex-dividend date is Wednesday, August 14th. This represents a $2.58 annualized dividend and a yield of 2.33%. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.
In other Eli Lilly And Co news, SVP Aarti S. Shah sold 1,800 shares of the company’s stock in a transaction dated Friday, April 5th. The shares were sold at an average price of $125.85, for a total transaction of $226,530.00. Following the completion of the sale, the senior vice president now directly owns 18,425 shares in the company, valued at $2,318,786.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Michael J. Harrington sold 16,000 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the sale, the vice president now owns 110,300 shares of the company’s stock, valued at $12,874,216. The disclosure for this sale can be found here. Insiders sold 40,112 shares of company stock valued at $4,820,705 over the last quarter. 0.11% of the stock is owned by company insiders.
Eli Lilly And Co Profile
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Featured Article: How is an ETF different from a mutual fund?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.